PLRX Pliant Therapeutics Forecast, Technical & Fundamental Analysis
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies... Show more
PLRX is expected to report earnings to rise 15.94% to -37 cents per share on August 10
Q2'26
Est.
$-0.37
Q1'26
Beat
by $0.03
Q4'25
Beat
by $0.01
Q3'25
Beat
by $0.13
Q2'25
Missed
by $0.05
The last earnings report on May 11 showed earnings per share of -31 cents, beating the estimate of -35 cents. With 425.51K shares outstanding, the current market capitalization sits at 71.83M.
A.I. Advisor
published General Information
General Information
a company which engages in the business of developing and commercializing novel therapies for fibrotic diseases
A.I.dvisor indicates that over the last year, PLRX has been loosely correlated with LXRX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PLRX jumps, then LXRX could also see price increases.
PLRX in downward trend: price dove below 50-day moving average on June 01, 2026
PLRX moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend. In of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for PLRX entered a downward trend on May 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PLRX's RSI Indicator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 71 cases where PLRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on PLRX as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PLRX just turned positive on June 17, 2026. Looking at past instances where PLRX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PLRX advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PLRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.435) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). PLRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). PLRX's P/S Ratio (3333.333) is very high in comparison to the industry average of (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
